This 24-week, open-label, Phase Ib, parallel-arm, multiple-dose trial assessed the pharmacokinetics, safety and tolerability of a once-monthly injection of aripiprazole (aripiprazole once-monthly) in 41 subjects with schizophrenia. The objective was to determine if aripiprazole plasma concentrations (at doses of 200, 300 and 400 mg) were within the therapeutic range observed for the oral tablet (10-30 mg). Completion rates were 36.4% (n = 4/11), 50.0% (n = 8/16) and 71.4% (n = 10/14) for the 200 mg, 300 mg and 400 mg groups, respectively. Patients were stabilized on oral aripiprazole (10 mg/day) before the first injection and received oral aripiprazole (10 mg/day) concomitantly with the first dose of aripiprazole once-monthly for 14 days. Administration of aripiprazole once-monthly at doses of 300 and 400 mg provided sustained mean aripiprazole plasma concentrations comparable with the concentration range observed following multiple consecutive daily doses of oral aripiprazole. In contrast, plasma concentrations following administration of aripiprazole once-monthly at a dose of 200 mg were below the therapeutic range and pharmacokinetic parameters were not proportional to the administered dose compared with the 300 mg and 400 mg doses. Treatment with aripiprazole once-monthly, at any dose, did not result in any clinically meaningful changes from baseline in extrapyramidal symptom scales, clinical laboratory tests, vital signs, or electrocardiogram parameters. The most common treatment-emergent adverse events were vomiting (13.3%, 300 mg; 14.3%, 400 mg), injection site pain (28.6%, 400 mg), upper respiratory tract infection (10%, 200 mg; 6.7% 300 mg; 14.3%, 400 mg) and tremor (6.7%, 300 mg; 21.4%, 400 mg). In conclusion, aripiprazole once-monthly at doses of 300 and 400 mg is a viable formulation for treatment of adults with schizophrenia.
Introduction
The long-term course of schizophrenia is frequently characterized by reduced social and occupational functioning, loss of independent living, impaired quality of life, substance abuse and an increased risk of suicidal and violent behavior (Wiersma et al., 2000) . Maintenance treatment with antipsychotics is, therefore, a key feature of long-term management. However, partial or non-adherence to medication is an important barrier in achieving long-term success (Velligan et al., 2009 ). Rates of non-adherence to antipsychotic medication are high and are associated with a significantly increased risk of relapse and hospitalization (Gilmer et al., 2004; Kane, 2006; Valenstein et al., 2006; Nasrallah, 2007) .
Long-acting injectable (LAI) antipsychotics relieve patients from the daily need to take medication and subsequently have the potential to improve adherence (Kane, 2006) . Furthermore, failure to attend an injection visit serves as a signal for treatment non-adherence (Lindenmayer, 2010) . Three new-generation antipsychotics with long-acting formulations are approved in the US and Europe for treatment of schizophrenia: risperidone LAI (Fleischhacker et al., 2003; Kane et al., 2003) , olanzapine LAI (Lauriello et al., 2008; Kane et al., 2010) and paliperidone palmitate (Hough et al., 2010) . These formulations are reviewed in detail elsewhere (Fleischhacker, 2009; Rauch, 2013) .
More recently, aripiprazole once-monthly, a long-acting injectable formulation of oral aripiprazole has been approved in the US for the treatment of schizophrenia. The established efficacy and safety profile of oral aripiprazole for treatment of schizophrenia and bipolar disorder (McIntyre et al., 2007; Stip and Tourjman, 2010) , alongside preliminary pharmacokinetic (PK) data from subjects receiving multiple daily doses of oral aripiprazole, made it a candidate for development into a longacting formulation. Two, 14-day studies investigating pharmacokinetics, tolerability and safety of oral aripiprazole in healthy volunteers showed that multiple once-daily doses of oral aripiprazole had linear pharmacokinetics (fixed dose: 5, 10, 15, and 20 mg; flexible dose: 10-30 mg/day) (Mallikaarjun et al., 2004) . Mean elimination half-lives for the fixed-dose and flexible-dose trial were 47-68 h and 59 h, respectively. Subjects generally reached steady state by Day 14. The C max at Day 14 for aripiprazole doses 10 to 30 mg/day was 163 to 452 ng/mL (Mallikaarjun et al., 2004) .
The current study evaluated the pharmacokinetics, tolerability and safety of three different doses (200, 300, and 400 mg) of aripiprazole once-monthly (administered as 5 monthly injections of aripiprazole once-monthly over a 4-month period) for treatment of adults with schizophrenia.
Methods

Study design
This 24-week, open-label, parallel-arm study assessed the pharmacokinetics, safety, and tolerability of aripiprazole once-monthly in adults with schizophrenia. The study consisted of two phases: a screening phase (up to 28 days), which included stabilization on oral aripiprazole; and a randomization/treatment assignment phase (24 weeks), in which patients received one of three different dose levels of aripiprazole once-monthly (200 mg, 300 mg or 400 mg [referred to as aripiprazole once-monthly-200, aripiprazole once-monthly-300 and aripiprazole once-monthly-400, respectively]) as five injections over a 4-month period (Fig. 1 ).
Dosing rationale
Aripiprazole plasma concentration-time profiles were simulated based on PK parameters for a single-dose of aripiprazole oncemonthly and from previous oral steady-state studies (BMS data on file). Based on these simulations, the lower 95% confidence interval of the minimum steady-state plasma drug concentrations during a dosing interval (C ss,min ) for aripiprazole once-monthly-300 and aripiprazole once-monthly-400 was expected to be above (or very close to) the C ss,min of daily dosing with 10 mg oral aripiprazole. An aripiprazole once-monthly dose of 200 mg was also chosen in the event of tolerability issues at higher doses and to provide further insight into dose plasma level continuity.
Simulation modeling also indicated that the maintenance of therapeutic concentrations observed with oral aripiprazole (10-30 mg) was best achieved by supplementing the initial aripiprazole once-monthly injection with oral aripiprazole (10 mg/day) for the first 14 days while aripiprazole concentrations derived from the once-monthly injection reached therapeutic levels. During screening, subjects taking antipsychotics other than aripiprazole were switched to oral aripiprazole 10 mg/day over a 14-day period and had to demonstrate stability for 14 days; subjects already receiving oral aripiprazole 10 mg/day had to demonstrate stability for 14 days; subjects on oral aripiprazole at doses N10 mg/day were downtitrated to 10 mg/day over a 14-day period in step sizes according to the investigator's discretion followed by an additional 14 days at 10 mg/day to demonstrate stability. b Up to 32 subjects were initially randomized to aripiprazole once-monthly-400 and aripiprazole once-monthly-300. A further 10 to 12 subjects were then assigned to receive aripiprazole once-monthly-200. All subjects received oral aripiprazole 10 mg for the first 14 days following the initial injection of aripiprazole once-monthly. The Week 1 visit was defined as Day 1 (the day of the first aripiprazole once-monthly injection); subsequent clinic visits occurred at the beginning of the study week within a visit window of ±1 day (e.g. the Week 2 visit occurred between Days 6 and 8).
c Subjects were permitted to resume oral aripiprazole or their prestudy antipsychotic medication at the investigator's discretion after Week 20 (after the 4-week post-injection PK sample was obtained). However, subjects were encouraged to complete the entire study, including the PK sample at Week 25 before resuming antipsychotics. PK = pharmacokinetic. Eligible subjects had to be stable on their current antipsychotic medication for at least 28 days or needed to be receiving oral aripiprazole at ≥10 mg/day prior to enrolment. To facilitate the transition from oral to injectable antipsychotic, all subjects were stabilized for ≥ 14 days on open-label oral aripiprazole (10 mg/day) during screening (Day − 28 to Day − 1). This entailed one of the following: subjects receiving oral aripiprazole 10 mg/day at enrolment needed to be stable for 14 days prior to entering the randomization/ treatment assignment phase; subjects on oral antipsychotics other than aripiprazole were switched to oral aripiprazole (10 mg/day over a 14-day period) and needed to be stable at that dose for ≥14 days prior to entering the randomization/treatment assignment phase; subjects on oral aripiprazole at doses N 10 mg/day were downtitrated to 10 mg/day over a 14-day period in step sizes based on the investigator's discretion, followed by an additional 14 days at 10 mg/day to demonstrate stability prior to randomization/treatment assignment.
Patients and treatment schedule
Following the screening phase, eligible subjects were randomized and assigned to aripiprazole once-monthly for a total of five injections (administered on Day 1, and at the beginning of Weeks 5, 9, 13 and 17) (Fig. 1) . Subjects received oral aripiprazole 10 mg for the first 14 days following the initial injection of aripiprazole once-monthly. After Week 20, subjects were permitted to resume their pre-study medication or to initiate treatment with another antipsychotic medication, including oral aripiprazole, at the investigator's discretion. However, subjects were encouraged to complete the entire study, including the final PK sample at Week 25 before resuming antipsychotics.
During the randomization/treatment assignment phase, weekly outpatient visits were made through Week 21, including an additional mid-week visit at Week 18.5 and at Weeks 23, 24 and 25. Week 24 was the protocol-defined end-of-treatment visit. The Week 1 visit was defined as Day 1 (the day of the first aripiprazole once-monthly injection); subsequent clinic visits occurred at the beginning of the study week within a visit window of ±1 day (e.g. the Week 2 visit occurred between Days 6 and 8).
Concomitant medications
Mood stabilizing medications, antidepressants, and other psychotropic agents were prohibited during the study and washed out ≥ 14 days prior to administration of aripiprazole once-monthly. Inhibitors and inducers of CYP3A4 and inhibitors of CYP2D6 were also not permitted. Benzodiazepines (lorazepam or lorazepam equivalent) or anticholinergics were permitted during the screening period for symptomatic relief, as clinically indicated. During the course of the study, benzodiazepine or anticholinergics could be administered for clinical indications other than prophylactic use, if deemed absolutely necessary by the treating physician [although not within 4 and 12 h, respectively, of extrapyramidal symptom (EPS) rating scale assessments].
Pharmacokinetic assessments
During aripiprazole once-monthly treatment, blood samples for measurement of aripiprazole and dehydro-aripiprazole plasma concentrations were collected pre-dose [i.e. on Day 1 (Week 1), and Weeks 5, 9, 13 and 17] as well as at Weeks 2, 3, 4, 6, 7, 8, 10, 11, 12, 14, 15 and 16. After the final dose (Week 17), samples were collected at 1, 2, 3, 4, 6, 8, 12 and 24 h, then at 2, 3, 4 and 5 days, and at 1 week (Week 18), 1.5 weeks (Week 18.5), 2 weeks (Week 19), 3 weeks (Week 20), 4 weeks (Week 21), 6 weeks (Week 23) and 8 weeks (Week 25). Subjects resuming oral aripiprazole or other antipsychotic medication after Week 20 were excluded from PK analyses at Weeks 23 and 25.
Adverse events
Adverse events (AEs) and safety assessments were reported for all subjects who received at least one injection of aripiprazole oncemonthly. Events were reported separately for the entire treatment period (beginning with the first aripiprazole once-monthly injection through to the last visit) and for the co-administration period (co-administration AEs were defined as all AEs with onset between the first and second monthly aripiprazole once-monthly injection, even though the last dose of coadministered oral aripiprazole was to occur on Day 14). For subjects discontinuing prior to the second aripiprazole once-monthly injection, all AEs were considered to have occurred in the co-administration interval up to the point of last contact.
Safety assessments
Extrapyramidal symptoms were monitored using the SimpsonAngus scale (SAS) (Simpson and Angus, 1970) , the Abnormal Involuntary Movement Scale (AIMS) (Guy, 1976a) , and the Barnes Akathisia Rating Scale (BARS) (Barnes, 1989) . Subjects were assessed at baseline, then every other week through Week 19 and at Weeks 20 and 24. Investigator assessment of local pain, tolerability and inflammation at the injection site was evaluated by examining the AE profile pertaining to injection-site reactions.
Psychotic symptoms were evaluated using data from the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) and Clinical Global Impressions -Severity (CGI-S) scale (Guy, 1976b) . The PANSS was performed at baseline and monthly during the treatment period and at Week 24. The CGI-S was completed at each weekly visit through Week 20 and at Week 24.
Pharmacokinetic analysis
PK concentration-time profiles were performed on subjects who received ≥3 doses of aripiprazole once-monthly and had PK samples collected through ≥4 weeks following their last dose. PK parameters were calculated based on data following the fifth injection of aripiprazole once-monthly. Primary PK parameters included the maximum and minimum steady-state plasma concentrations of aripiprazole during the dosing interval (C ss,max , C ss,min ) and the area under the concentration-time curve during a dosing interval at steady-state (AUCτ). Secondary PK parameters for aripiprazole included the time to maximum (peak) plasma concentration (t max ), the average plasma steady-state drug concentration during a dosing interval (C ss,avg ), the apparent terminal-phase disposition rate constant (first-order) (λ z ), and the terminal-phase elimination half-life (t 1/2,z ).
Statistical analysis
Primary and secondary PK parameters and safety data were summarized using descriptive statistics. Mean changes from baseline were recorded at each visit for the PANSS total score and CGI-S score, and analyzed using an analysis of covariance.
Results
The disposition of all 41 subjects who entered the randomization/ treatment assignment phase is summarized in Table 1 . Completion rates were 36.4% (4/11), 50.0% (8/16) and 71.4% (10/14) for aripiprazole once-monthly-200, -300 and -400, respectively. The most common reasons for discontinuation were withdrawal of consent for aripiprazole once-monthly-200 (n = 5), AEs for aripiprazole once-monthly-300 (n = 4), and 'met withdrawal criteria' for aripiprazole once-monthly-400 (n = 3) ( Table 1) . Baseline demographic characteristics and psychiatric history are summarized in Table 2 .
Concomitant medications
The most commonly used concomitant medications during treatment with aripiprazole once-monthly are shown in Table 3 . A total of seven patients received concomitant medication with either risperidone or quetiapine (Table 3 ). In the majority of cases (5/7), these antipsychotics were given for treatment of psychosis/schizophrenia ≥ 3 weeks after the last dose of aripiprazole once-monthly was administered (i.e. following Week 20). In one of the other two cases, a patient was switched from oral aripiprazole to oral risperidone following the initial dose of aripiprazole once-monthly but this patient subsequently discontinued the study due to an AE of worsening of schizophrenia. The final patient received risperidone for a period of approximately 4 weeks as part of a treatment plan for schizophrenia following an error with the fourth injection, whereby an unknown dose of aripiprazole once-monthly was administered instead of aripiprazole once-monthly-300.
Pharmacokinetics
Mean plasma concentrations of aripiprazole prior to the third, fourth, and fifth injections of aripiprazole once-monthly were: aripiprazole oncemonthly-200: 60.3, 71.1, and 68.9 ng/mL; aripiprazole once-monthly-300: 128, 185, and 175 ng/mL; and aripiprazole once-monthly-400: 152, 179, and 190 ng/mL (Fig. 2a) . Aripiprazole plasma concentrations were quantifiable in all subjects with evaluable data at 2 months following the last injection and were in the range 37.9-157 ng/mL and 32.1-188 ng/mL for subjects receiving aripiprazole once-monthly-300 (n = 3) and aripiprazole once-monthly-400 (n = 6), respectively.
For aripiprazole once-monthly-200, aripiprazole plasma concentrations were quantifiable in 3 subjects at 6 weeks after the last injection and were in the range 2.45-88.9 ng/mL.
The mean plasma concentrations of dehydro-aripiprazole prior to the third, fourth, and fifth aripiprazole once-monthly injections were: aripiprazole once-monthly-200: 19.6, 22.2, and 19.5 ng/mL; aripiprazole once-monthly-300: 42.8, 57.4, and 53.1 ng/mL; and aripiprazole oncemonthly-400: 46.6, 55.3, and 57.7 ng/mL (Fig. 2b) . Dehydroaripiprazole plasma concentrations were quantifiable in all subjects with evaluable data at 2 months following the last injection and were in the range 10.7-58.4 ng/mL and 10.3-77.4 ng/mL for subjects receiving aripiprazole once-monthly-300 (n = 3) and aripiprazole once-monthly-400 (n = 6), respectively. For aripiprazole oncemonthly-200, dehydro-aripiprazole plasma concentrations were quantifiable in 3 subjects at 6 weeks after the last injection and were in the range 1.33-26.8 ng/mL.
After the fifth injection of aripiprazole once-monthly-300 or aripiprazole once-monthly-400, PK parameters (C ss , max , AUCτ, C ss,min , and C ss,avg ) of aripiprazole and dehydro-aripiprazole increased proportionally to the administered dose (Table 4) . When compared with the 300 mg and 400 mg doses, PK parameters for aripiprazole oncemonthly-200 were not proportional to the administered dose. The ratio of dehydro-aripiprazole to aripiprazole after the last injection of aripiprazole once-monthly for mean C ss,max and AUCτ PK parameters ranged from 29.1 to 33.2.
Safety and tolerability
Treatment-emergent AEs (TEAEs) at an incidence of ≥ 5% are summarized in Table 5 . Most TEAEs were classified as mild or moderate in intensity. Four subjects in the aripiprazole once-monthly-400 group reported injection-site pain as a common TEAE (no injection site reaction TEAEs were reported in the 200 mg and 300 mg groups). One subject who reported injection-site pain following the fifth injection also experienced injection-site discomfort following the first oncemonthly injection. All injection site reaction TEAEs were considered mild in intensity and resolved without sequelae. No AEs pertaining to suicide or attempted suicide were reported.
Approximately 45% of TEAEs (n = 46/102) were reported during the co-administration period. The incidence of TEAEs during coadministration was 40.0% (n = 4/10), 60.0% (n = 9/15) and 57.1% (n = 8/14) for the aripiprazole once-monthly-200, -300 and -400 groups, respectively. Four subjects (10.3%) discontinued with treatment due to TEAEs; three discontinuations occurred in the aripiprazole once-monthly-300 group (one each due to drug dependence, worsening of psychosis and worsening schizophrenia). Withdrawal due to worsening of psychosis also occurred in a subject receiving aripiprazole once-monthly-200. All TEAES leading to discontinuation of study medication occurred during the co-administration period.
Mean changes in objective rating movement scales from baseline to last visit were minimal and not considered to be clinically meaningful. No change in SAS scores occurred for any aripiprazole once-monthly doses. No change in AIMS score occurred for patients receiving aripiprazole once-monthly-200, whereas small changes were observed in patients receiving aripiprazole once-monthly-300 (0.4, baseline = 0.2) and aripiprazole once-monthly-400 (−0.4, baseline = 0.4). The baseline BARS score (0.1) and change from baseline to last visit (0.1) was the same across all three doses.
Mean changes in weight from baseline to last visit were +2.1 kg, +1.2 kg and +2.2 kg for aripiprazole once-monthly-200, -300 and -400, respectively. Clinically significant weight gain (≥7% from baseline) was reported in 1/9 (11.1%), 2/14 (14.3%) and 3/12 (25.0%) patients in the aripiprazole once-monthly-200, -300 and -400 groups, respectively. Two subjects (one each for aripiprazole once-monthly-300 [7.1%] and Table 1 Disposition of all enrolled subjects. b Subjects were withdrawn from the study if they met exclusion criteria, received concomitant medications or were non-compliant with study medication at any time.
Subjects
Of the 5 subjects who met withdrawal criteria, three subjects were non-compliant, one relocated, and one became pregnant. c Received at least three doses of aripiprazole once-monthly and had pharmacokinetic samples collected through at least 4-weeks after the last dose of aripiprazole once-monthly. d Received at least one dose of aripiprazole once-monthly.
-400 [8.3%] groups) experienced a clinically significant weight loss (≥7% from baseline).
No clinically relevant changes from baseline were observed for serum chemistry laboratory tests, hematology results, urinalysis, prolactin levels, or vital signs. Three subjects (n = 1 [7.1%] in the aripiprazole once-monthly-300 group and n = 2 [22.2%] in the aripiprazole once-monthly-200 group) had creatinine phosphokinase (CPK) levels that met the criteria for potential clinical significance (≥3 × upper limit of normal range [ULN]), none were reported as TEAEs and all of these patients had elevated CPK levels at baseline. One subject receiving aripiprazole once-monthly-300 [7.1%] had elevated prolactin values of potential clinical significance (N ULN) but this was not reported as a TEAE.
No worsening of psychotic symptoms was observed during the study period, as assessed by PANSS total scores and CGI-S scores. Mean reductions in PANSS total score from baseline to Week 24 (last observation carried forward [LOCF]) were small (−0.8 to −1.3) with no significant differences across dose groups. Similarly, CGI-S scale scores for the three treatment groups showed only small changes (−0.2 to 0.1) from a baseline value of 3.0 to 3.3 (mildly ill) at every visit week during the study period.
Discussion
Monthly administration of 300 and 400 mg of aripiprazole oncemonthly had a PK profile consistent with that of multiple, consecutive daily oral doses of aripiprazole (10-30 mg) (Mallikaarjun et al., 2004) . Mean maximum and trough plasma concentrations after 5 monthly injections of aripiprazole once-monthly-300 and -400 confirmed dosing simulations. The aripiprazole once-monthly formulation was designed to provide sustained aripiprazole plasma concentrations over the course of the dosing interval. As shown here, steady-state plasma concentrations for the 400 mg dose ranged from a mean C max of 316 ng/mL to a mean C min of 212 ng/mL. The upper limit of this concentration range (C max ) approximates steady-state plasma levels achieved after oral dosing of 20-30 mg/day, and trough concentrations (C min ) approximate steady-state plasma levels achieved after oral dosing of 15-20 mg/day (Mallikaarjun et al., 2004; Sparshatt et al., 2010) . Aripiprazole once-monthly-200 did not result in mean aripiprazole trough plasma concentrations comparable to therapeutic concentrations of 10-30 mg of once-daily oral aripiprazole, suggesting that the 200 mg injectable dose may be below a meaningful therapeutic threshold. Ratios of dehydro-aripiprazole to aripiprazole for mean C ss,max and AUCτ PK parameters after the last injection of aripiprazole once-monthly were 29-33%, similar to the 33-39% ratio achieved with a single 15 mg daily dose of oral aripiprazole in healthy volunteers (Mallikaarjun et al., 2008) .
A 2-week oral supplementation regimen was used to ensure a smooth transition between the oral and extended-release formulations while concentrations of aripiprazole derived from the oncemonthly injection reached therapeutic levels. This 2-week overlap was based on an exploratory analysis of single-dose aripiprazole once-monthly and oral steady-state studies. Aripiprazole PK profiles Table 2 Baseline demographic and psychiatric characteristics for the randomized population. 66.4 (9.9) CGI-S score, mean (SD) 3.2 (0.6) 3.1 (0.5) 3.3 (0.6) 3.2 (0.6) SD, standard deviation; BMI, body mass index; PANSS, Positive and Negative Syndrome Scale; CGI-S, Clinical Global Impressions -Severity. a n = 15 for aripiprazole once-monthly-300 and n = 40 for total.
Table 3
Concomitant medications received during treatment with aripiprazole once-monthly (N5.0% subjects overall). reported in our study showed that steady-state maximum aripiprazole concentrations were reached within 5-7 days, supporting this switching strategy. In our study, patients received oral supplementation with 10 mg oral aripiprazole. However, the recently approved label for once-monthly aripiprazole is based on oral supplementation with oral aripiprazole at 10 mg to 20 mg for 14 days, as well as allowing patients to continue with their existing oral atypical antipsychotic during the overlap period (Otsuka Pharmaceutical Co., Ltd., 2013) . Additionally, a separate study has shown that switching patients to aripiprazole once-monthly from oral atypical antipsychotics other than oral aripiprazole was well tolerated, with an AE profile consistent with reports of aripiprazole once-monthly concomitant with oral aripiprazole (Potkin et al., 8-11 November 2012) . Psychopathological symptoms remained stable during the study period and the majority of TEAEs reported were mild or moderate. Similar to other currently available long-acting antipsychotic formulations (Chue et al., 2005; Hough et al., 2010; Kane et al., 2010) , the safety and tolerability of the aripiprazole once-monthly formulation a The x-axis shows the time at the end of each week following the first injection of aripiprazole once-monthly. Accordingly, the value at Week 24 corresponds to the PK assessment taken at the beginning of Week 25 and monthly injections are shown at baseline and Weeks 4, 8, 12 and 16, corresponding to study visits at the beginning of Weeks 1, 5, 9, 13 and 17, respectively. are comparable to those of the oral formulation (Marder et al., 2003) . However, these comparisons of aripiprazole are between individual reports as direct comparative studies are not available.
All three doses of aripiprazole once-monthly demonstrated acceptable safety and tolerability. Of note was a higher discontinuation rate with aripiprazole once-monthly-200 compared with aripiprazole oncemonthly-300 and -400. It could be speculated that the higher discontinuation rate in patients receiving aripiprazole once-monthly-200 may have been a result of sub-therapeutic plasma concentrations. Although these patients did not show a higher proportion of worsening of psychosis symptoms, the open-label study design and the limited number of subjects who completed aripiprazole once-monthly-200 limit interpretation of the potential correlation between efficacy and PK results.
The majority of TEAEs were reported as mild or moderate. The most common TEAEs (overall incidence) were vomiting, injection-site pain, upper respiratory tract infection and tremor, all of which occurred in 10.3% of the total population. Injection-site pain was only reported in aripiprazole once-monthly-400 patients despite equivalent absolute injection volumes suggesting that administration of the injectable formulation was generally well tolerated. A total of 17.1% of subjects showed weight gain of ≥7% from baseline, with the highest incidence in patients receiving aripiprazole once-monthly-400 (25.0%). These values, although higher than previously reported in a larger randomized controlled trial , could be inflated due to the relatively small sample size. No new safety concerns were raised regarding laboratory parameters, vital signs, electrocardiograms or EPS findings. The incidence of potentially clinically relevant CPK elevation all occurred in patients with elevated levels at baseline. No laboratory values of potential clinical significance were identified for patients receiving aripiprazole once-monthly-400.
Collectively, the PK profile and the clinical data suggest that aripiprazole once-monthly at doses of 300 and 400 mg appear to be most suitable for further investigation in the treatment of schizophrenia. These findings are supported by recently published clinical data showing the efficacy of aripiprazole once-monthly-300 and -400 mg in patients with schizophrenia (Fleischhacker et al., 2-6 December 2012; Kane et al., 2012) .
Limitations
A limitation of our study is the low numbers of subjects included in each dose category; however, the study was designed to be exploratory with findings intended to provide guidance for design of future studies. Our findings were specific to a population that was not permitted inhibitors and inducers of CYP3A4 and inhibitors of CYP2D6. However, aripiprazole once-monthly can be administered to patients PK, pharmacokinetic; SD, standard deviation; AUC, area under the curve; ND, not determined. a n = 4. b n = 6. c C ss,min = concentration 28 days post-injection. Table 5 Summary of adverse events with an incidence N5% of all randomized subjects (n = 39). 2 (20.0) 0 (0.0) 1 (7.1) 3 (7.7) Akathisia 1 (10.0) 1 (6.7) 1 (7.1) 3 (7.7) Insomnia 1 (10.0) 1 (6.7) 1 (7.1) 3 (7.7) Cough 1 (10.0) 0 (0.0) 1 (7.1) 2 (5.1) Back pain 0 (0.0) 1 (6.7) 1 (7.1) 2 (5.1) Anxiety 0 (0.0) 1 (6.7) 1 (7.1) 2 (5.1) Hallucination, auditory 0 (0.0) 1 (6.7) 1 (7.1) 2 (5. receiving these medications with dose adjustments (Otsuka Pharmaceutical Co., Ltd., 2013). Seven patients received concomitant medication with either risperidone or quetiapine during the study. These medications were largely administered for treatment of psychosis/schizophrenia during the period of extended PK assessments at a point when the next injection of aripiprazole once-monthly would have been due. Despite these limitations, the consistency in mean plasma concentration levels across multiple doses of aripiprazole once-monthly implies that the PK findings reflect the sustained concentrations of aripiprazole provided by the once-monthly dosing regimen.
Conclusions
Injections of aripiprazole at doses of 300 and 400 mg provided sustained concentrations of aripiprazole supporting a once-monthly dosing schedule, with a PK profile comparable to that of multiple, consecutive daily doses of oral aripiprazole (10-30 mg). Aripiprazole once-monthly appears to be a new option for the long-term management of schizophrenia.
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